General
Preferred name
NU6140
Synonyms
Cdk2 inhibitor IV ()
NU 6140 ()
P&D ID
PD017865
CAS
444723-13-1
Tags
available
drug candidate
Drug indication
Discovery agent
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION This compound is a highly cell-permeable purine compound that acts as an ATP-competitive inhibitor of cyclin dependent kinases (CDKs). In vitro assays show that it is 36-fold selective for CDK2 compared to other CDKs tested .
DESCRIPTION NU6140 is a selective CDK2-cyclin A inhibitor (IC50, 0.41 ¦ÌM), exhibits 10- to 36-fold selectivity over other CDKs[1]. NU6140 also potently inhibits Aurora A and Aurora B, with IC50s of 67 and 35 nM, respectively[2]. Enhances the apoptotic effect, with anti-cancer activity[1][2].
PRICE 85
DESCRIPTION NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 ??M). It shows 10- to 36-fold selectivity over other CDKs. NU6140 also effectively inhibits Aurora A and Aurora B (IC50s: 67 and 35 nM, respectively). It also enhances the apoptotic effect and has anti-cancer activity.
DESCRIPTION This compound is a highly cell-permeable purine compound that acts as an ATP-competitive inhibitor of cyclin dependent kinases (CDKs). In vitro assays show that it is 36-fold selective for CDK2 compared to other CDKs tested , however users should be aware that it also potently inhibits Aurora kinases A and B . (GtoPdb)
DESCRIPTION NU6140 is a cyclin-dependent kinase 2 (cdk2) inhibitor, and induces cell-cycle arrest at the G2-M phase. NU6140 also potently inhibits Aurora A and Aurora B, with IC50s of 67 and 35 nM, respectively. (BOC Sciences Bioactive Compounds)
DESCRIPTION NU6140 is a selective inhibitor of CDK2-cyclin A (IC50, 0.41 μM). It shows 10- to 36-fold selectivity over other CDKs. NU6140 also effectively inhibits Aurora A and Aurora B (IC50s: 67 and 35 nM, respectively). It also enhances the apoptotic effect and has anti-cancer activity. (TargetMol Bioactive Compound Library)
DESCRIPTION Potent and selective PDGFRbeta inhibitor (Tocris Bioactive Compound Library)
Compound Sets
8
BOC Sciences Bioactive Compounds
nu6140-cas-444723-13-1-item-84-272252
Cayman Chemical Bioactives
17271
CDK inhibitor database (CDKiDB)
DrugMAP
DMCUSG3
Guide to Pharmacology
5949
MedChem Express Bioactive Compound Library
HY-107419
TargetMol Bioactive Compound Library
T16359
Tocris Bioactive Compound Library
3301
External IDs
22
Properties
(calculated by RDKit )
Molecular Weight
422.24
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
8
Ring Count
4
Aromatic Ring Count
3
cLogP
4.54
TPSA
96.03
Fraction CSP3
0.48
Chiral centers
0.0
Largest ring
6.0
QED
0.55
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Aurora A
Aurora B
Aurora Kinase
CDK
CDK1/CyclinB
CDK2/CyclinA
CDK4/CyclinD
CDK5/p25
CDK7/CyclinH
Primary Target
Cyclin-Dependent Protein Kinases
MOA
Inhibitor
Pathway
Cell Cycle/Checkpoint
Chromatin/Epigenetic
Cell Cycle/DNA Damage
Epigenetics
Source data